The Carlsbad-based biopharmaceutical firm expects to launch the global ASCENTRA-UC study in the latter half of 2026. This trial aims to recruit 204 patients across North America and Europe, comparing two distinct dosage levels against a placebo. Management anticipates primary results from this evaluation by the second half of 2027.

Following the recent market uptick to $2.12 per share, Palisade Bio is already looking beyond its initial target. The company intends to file a separate application in late 2026 to expand the study of PALI-2108 into the treatment of Crohn's disease, signaling a broader strategy to address inflammatory bowel conditions.